Bioventus Inc. BVS
NASDAQ
| 06/27/2026 | 03/28/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 15.99% | -16.35% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 15.99% | -16.35% | |||
| Cost of Revenue | 15.06% | -15.88% | |||
| Gross Profit | 16.41% | -16.56% | |||
| SG&A Expenses | 5.63% | -5.38% | |||
| Depreciation & Amortization | -5.96% | -14.65% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.15% | -9.53% | |||
| Operating Income | 110.75% | -59.08% | |||
| Income Before Tax | 238.90% | -68.06% | |||
| Income Tax Expenses | -3,759.72% | 117.98% | |||
| Earnings from Continuing Operations | 817.51% | -77.21% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -231.81% | 67.50% | |||
| Net Income | 974.24% | -78.90% | |||
| EBIT | 110.75% | -59.08% | |||
| EBITDA | 47.70% | -25.71% | |||
| EPS Basic | 964.15% | -78.97% | |||
| Normalized Basic EPS | 184.12% | -70.31% | |||
| EPS Diluted | 1,075.00% | -80.88% | |||
| Normalized Diluted EPS | 184.05% | -70.58% | |||
| Average Basic Shares Outstanding | 0.85% | 0.41% | |||
| Average Diluted Shares Outstanding | 1.19% | 1.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||